Revolution Plus is a drug owned by ZOETIS INC. It is protected by 4 US drug patents filed from 2019 to 2033. Out of these, 3 patents are active and 1 patent has expired. Details of Revolution Plus’s patents and their expiration are given below.
Exclusivity Information
Revolution Plus holds 1 exclusivity out of which 0 have expired. Its last outstanding exclusivity is set to expire in 2026. Details of Revolution Plus's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NCI | Dec 14, 2026 |
About Revolution Plus
Revolution Plus is a drug
owned by ZOETIS INC.
Revolution Plus uses
Sarolaner, Selamectin as the active
ingredients.
Active Ingredient:
Revolution Plus uses
Sarolaner,
Selamectin
as the active ingredients.
Check out other Drugs and Companies using
Sarolaner, Selamectin ingredient.